[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
April 1985

Arterial Infusion of Dacarbazine and Cisplatin for Recurrent Regionally Confined Melanoma

Author Affiliations

From the Departments of Surgery (Dr Frost), Clinical Immunology and Biological Therapy (Drs Patt and Mavligit), and Diagnostic Radiology (Drs Chuang and Wallace), The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston. Dr Frost is a fellow of the American Cancer Society.

Arch Surg. 1985;120(4):478-480. doi:10.1001/archsurg.1985.01390280068015
Abstract

• We treated nine patients who had metastatic malignant melanoma confined to one extremity (8/9) or the vulva (1/9) with arterial dacarbazine and cisplatin at respective doses of 800 and 90 mg/sq m. We percutaneously introduced catheters into the extremity or regional artery under fluoroscopy by the Seldinger technique, removed them at the end of the infusions, and repositioned them at four-week intervals for repeated treatment cycles. One patient achieved a complete remission, three patients had partial remissions, and five patients' disease was stable. The group median survival will exceed 19 months. Three patients with stable disease died 6,18, and 19 months after treatment initiation, respectively. The toxic effects were primarily nausea and vomiting, pain in the infused extremity, and local erythema. Arterial dacarbazine and cisplatin offer a more effective and less toxic alternative to higher-dose single-agent arterial cisplatin for locally advanced malignant melanoma.

(Arch Surg 1985;120:478-480)

References
1.
Kopf AW, Bart RS, Rodriquez-Sains RS, et al: Malignant Melanoma . New York, Masson Publishing USA Inc, 1979, pp 1-3.
2.
Luce JK:  Chemotherapy of malignant melanoma . Cancer 1972;30: 1604-1615.Article
3.
McBride CM, McMurtrey MJ, Copeland EM, et al:  Regional chemotherapy by isolation-perfusion . Int Adv Surg Oncol 1978;1:1-9.
4.
McKneer G, Cantin J:  Local failure in the treatment of melanoma: The Janeway lecture . AJR 1957;99:791-808.Article
5.
Bellet RE, Mastrangelo MJ, Bred D, et al:  Chemotherapy of malignant melanoma , in Clark WH, Goldman LI, Mastrangelo MJ (eds): Human Malignant Melanoma . New York, Grune & Stratton Inc, 1979, pp 325-354.
6.
Einhorn LH, McBride CM, Luce JK, et al:  Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide for malignant melanoma . Cancer 1973;32:749-755.Article
7.
Krementz ET, Carter RD, Sutherland CM, et al:  The use of regional chemotherapy in the management of malignant melanoma . World J Surg 1979;3:289-304.Article
8.
Calvo DB, Patt YZ, Wallace S, et al:  Phase I-II trial of percutaneous intra-arterial cis-diamminedi-chloroplatinum (II) for regionally confined malignancy . Cancer 1980;45:1278-1283.Article
9.
Charnsangavej C, Chuang VP, Wallace S, et al:  Angiographic appearance of recurrent malignant melanoma before and after intra-arterial chemotherapy . Radiology 1982;142:347-349.Article
10.
Friedman MA, Kaufman DA, Williams JE, et al:  Combined DTIC and cis-dichlorodiammineplatinum (II) therapy for patients with disseminated melanoma: A Northern California Oncology Group study . Cancer Treat Rep 1979;63:493-495.
11.
Sugarbaker EV, McBride CM:  Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities . Cancer 1976;37:188-198.Article
12.
Shingleton WW:  Perfusion chemotherapy for recurrent melanoma of extremity: A progress report . Ann Surg 1969;169:969-973.Article
13.
Bulman AS, Crawford WJ:  Isolated limb perfusion with melphalan in the treatment of malignant melanoma . Br J Surg 1980;67:660-662.Article
14.
Hafstrom L, Jonsson PE:  Hyperthermic perfusion of recurrent malignant melanoma on the extremities . Acta Chir Scand 1980;146:313-318.
15.
Golomb FM:  Perfusion of melanoma: One hundred five isolated perfusions in 92 patients . Oncology 1972;26:197-205.Article
16.
Stehlin JS, Giovanella BC, Ipolyi PD, et al:  Results of hyperthermic perfusion for melanoma of the extremities . Surg Gynecol Obstet 1975;140: 339-348.
17.
Krementz ET, Carter DR, Sutherland CM, et al:  Malignant melanoma of the limb: An evaluation of chemotherapy by regional perfusion , in McBride CM, Smith JL (eds): Neoplasms of the Skin and Malignant Melanoma . Chicago, Year Book Medical Publishers, 1975, pp 375-400.
18.
Rochlin DB, Wagner DE, Rochlin S:  The therapy of malignant melanoma as treated by regional perfusion , in McCarthy WH (ed): Melanoma and Skin Cancer: Proceedings of the International Cancer Conference . Sydney, Australian Cancer Society International Union Against Cancer, 1972, pp 443-451.
19.
Davis CD, Ivins JC, Soule EH:  Mayo clinic experience with isolated limb perfusion for invasive malignant melanomas of the extremities: A retrospective study of long-term results and complications . Pigment Cell 1976;2:379-385.
20.
Collins JM:  Pharmacologic rationale for regional drug delivery . J Clin Oncol 1984;2:498-504.
21.
Savlov ED, Hall TC, Oberfield RA:  Intra-arterial therapy of melanoma with dimethyl triazeno imidazole carboxamide . Cancer 1971;28: 1164-1165.Article
22.
Lokich J, Curt G:  Phase I-II studies of continuous infusion methotrexate (MTX) and combined 5-fluorouracil (FU) plus methotrexate (MTX) . Proc Am Soc Clin Oncol 1984;3:32.
×